Corleen M. Roche - 06 Aug 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Financial Officer
Signature
/s/ Corleen Roche
Issuer symbol
IOVA
Transactions as of
06 Aug 2025
Net transactions value
$0
Form type
4
Filing time
08 Aug 2025, 16:06:19 UTC
Previous filing
16 Apr 2025
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Roche Corleen M. Chief Financial Officer C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS /s/ Corleen Roche 08 Aug 2025 0001857905

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Stock Option (right to buy) Award $0 +300,000 $0.000000 300,000 06 Aug 2025 Common stock 300,000 $2.58 Direct F1
transaction IOVA Restricted Stock Units Award $0 +150,000 $0.000000 150,000 06 Aug 2025 Common stock 150,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.